Opexa Advances Monocyte Derived Islet Technology to Proof of
Principle in stz-induced NOD/SCID Mice
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 -
OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, presentedposter presentations at the 5th International Society for Stem CellResearch Annual Meeting (ISSCR) in Cairns, Queensland, Australiafrom June 17-20 and at the 13th Annual Meeting of the InternationalSociety for Cel...
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 -
OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/IIextension clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In this one-year,8-subject extension clinical trial...
Opexa Presents Tovaxin Research at Federation of Clinical
Immunology Societies Annual Meeting
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 -
OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, made a posterpresentation at the 2007 Annual Meeting of the Federation ofClinical Immunology Societies (FOCIS) in San Diego June 7-11 at theSheraton San Diego Hotel & Marina. The poster, entitled"Identifying New Immuno...
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Dose Escalation Trial with Tovaxin for Multiple Sclerosis
THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 -
OpexaTherapeutics, Inc. (NASDAQ: OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/II doseescalation clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis. In this one-year, 10-subjectdose escalation clinica...